HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Akero Therapeutics, maintaining a price target of $50.
September 17, 2024 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Akero Therapeutics, maintaining a price target of $50, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst suggests a positive outlook for Akero Therapeutics, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100